ERBB2 and triple-negative breast carcinoma: Mammary tumor E0771 and 4T1 syngeneic mouse models have been implemented to study drug efficacy including novel immune-oncology drugs for human luminal B, Her2 positive, and stage IV triple negative breast cancer [6,7,44,45,46,47,48].